Varta
← Back to stories

From The Hindu

Center-Left Owned by Kasturi & Sons Ltd.

Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth

Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth

What each side is saying

One outlet's own words from each side of the spectrum. Quoted, not summarised.

  • left · 1 outlet

    The O2C business emerged as a key growth driver, with revenue surging 44.2% YoY, reflecting a sharp rise in crude and product price.

    — The Hindu

  • right · 1 outlet

    PB Fintech on Friday reported a strong jump in profit and revenue for the July-September quarter. This and more in today’s ETtech Top 5.

    — The Economic Times

RSS excerpt

Excluding the exceptional items, adjusted net profit stood at ₹3,162 crore.

Coverage arrived over 2 hours — first from The Economic Times, latest from The Hindu.

✓ Corroborated Coverage ⚡ Cross-Spectrum Consensus 2 news outlets reporting

Fact-Check & Bias Analysis

Verified by independent outlets with different editorial leanings.

Coverage Bias Distribution

Based on 2 reporting publishers
Left / Center-Left 1 (50%)
Center 0 (0%)
Center-Right / Right 1 (50%)

Compare all reporting outlets (2)

The Hindu Center-Left Kasturi & Sons Ltd. Current article

Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth

Excluding the exceptional items, adjusted net profit stood at ₹3,162 crore.

Read full article at The Hindu ↗

Read more news

See all latest stories →